How can you not wet your shoes? The global pharmaceutical industry has fallen to its lowest rate in 25 years

Although it is known as "safe haven" because it is a defensive industry, in this protracted financial turmoil, the pharmaceutical industry is also difficult to do "dripping water", especially for the European and American markets, the patent medicine expired, research and development difficulties and the Government strictly controlled the impact of pharmaceutical consumption relatively large.　　Global drug sales grew at the lowest rate in 25 years in 2009, according to a report released recently by a US market research agency. Global sales will only increase 2.5%~3.5% the agency downgraded its forecast for the pharmaceutical industry this year, with global drug sales growing only 2.5%~3.5% in 2009, at a total of 750 billion ~7600 billion, below its growth rate in October last year 4.5%~5.5% A total of 820 billion dollars in projections.　　This growth rate is the lowest in the past 25 years. In the past year, growth in the U.S. pharmaceutical industry, which accounts for almost half of global drug sales, has stalled. U.S. prescription drug sales rose by only 1.3% in 2008, to $291 billion trillion, and prescription drug sales grew by only 0.9%.　　The U.S. contribution to the global pharmaceutical industry's growth rate will fall from 42% in 2000 to 9% in 2009.　　Drug enterprises to accelerate mergers and acquisitions, imitation "winter" in the extreme deep cold, the major drug companies have a weapon to keep warm. The preferred approach is mergers and acquisitions. This year, the pharmaceutical industry has been mergers and acquisitions, only large cases of Pfizer annexation Wyeth, Merck merger first-Ling and Roche consultation fee gene, and other small mergers and acquisitions.　　Although the long-term effect of large-scale mergers is a matter of opinion, this approach can be a rapid combination of performance, short-term is a contingency strategy. Then the restructuring of the product structure.　　Many of the drug giants that have previously been devoted to new drug research have begun to dabble in "invisible" generic drugs. Pfizer's acquisition of Wyeth said that the product structure to diversify the representative Johnson learning. Sanofi-Aventis has also recently acquired several generics companies in the Czech Republic, Mexico and Brazil. While it also says it wants to invest more in the field of patented drugs and vaccines that have been good in the past, it needs new growth. Novartis, which already has a generic drug business, has increased its investment in the business, Joerres, the global chief executive of the generics division, said in a recent visit to China that the global generic drug market will grow by more than 9% per cent in 2008 to 2013, with Asian markets growing by as much as 12%, The global market for generic drugs has reached $80 billion trillion last year and is expected to reach $135 billion in 2013.　　To this end, the company to increase the speed of the introduction of drugs to China, on the other hand, actively expand sales channels, planning will be located in Zhongshan, Guangdong factory built in China pharmaceutical production base.　　2 years later China may be the third largest pharmaceutical market However, despite the weakness of growth in developed countries, the emerging markets of developing countries are still promising. The agency's report predicts that from now until 2013, including Canada, France, Germany, Italy, Japan, West classTeeth and the UK's "mature pharmaceutical market" growth rate will be between 1%~4%.　　Emerging markets such as China, Brazil and Mexico are growing fast, and 2013 growth will reach 13%~16%. Meanwhile, the seven largest emerging pharmaceutical markets in 2009 (China, Brazil, Mexico, South Korea, India, Turkey and Russia) will contribute half as much to the global pharmaceutical market.　　China is now the world's sixth-largest pharmaceutical market, and the agency predicts China will become the third largest pharmaceutical market by 2011. Newspaper reporter Li Yifi